Oncolytics Biotech® Announces Upcoming Annual General Meeting and Second Quarter Financial Results
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Oncolytics Biotech (NASDAQ: ONCY), a clinical-stage immunotherapy company focused on pelareorep development, has scheduled its 2025 Annual General Meeting for August 8, 2025, at 10:00 a.m. ET. The meeting will be held virtually, with CEO Jared Kelly providing a corporate update and discussing strategic milestones for 2025 after the formal shareholder voting.
The company will also release its second quarter 2025 financial results before market opening on the same day. Shareholders can access detailed voting information through the Management Information Circular dated June 18, 2025, available on the company's website and in securities filings.
Details
News Market Reaction – ONCY
On Aug 5, the day this news came out, ONCY closed 7.58% above the previous close.
Data tracked by StockTitan Argus for the Aug 5 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The management team will provide a brief corporate update after the formal portion of the shareholder meeting
To access the Meeting as a guest only (non-voting attendee):
- Visit the webcast site: https://virtual-meetings.tsxtrust.com/en/1824/
- Click the button "I am a Guest" and complete the form
- If necessary, provide the case-sensitive password: onc2025
Information on how to vote your shares by proxy and attend the Meeting as a shareholder is available in the Company's most recent Management Information Circular (the "Circular") dated June 18, 2025. The Circular is available on the Reports page of the investor relations section of the Company's website at https://oncolyticsbiotech.com/investor-overview/filings/reports/ and in Canadian and American securities filings.
Registered shareholders (who have not appointed a proxyholder) and duly appointed proxyholders (including non-registered shareholders who appoint themselves as proxyholders) will be able to virtually attend the Meeting and vote in real-time, provided they are connected to the internet. Non-registered shareholders who have not properly appointed themselves as proxyholder will be able to attend the Meeting as guests but will not be able to vote at the Meeting.
About Oncolytics Biotech Inc.
Oncolytics is a clinical-stage biotechnology company developing pelareorep, an intravenously delivered immunotherapeutic agent. Pelareorep has demonstrated promising results in two randomized Phase 2 studies in metastatic breast cancer and early-phase studies in pancreatic and colorectal cancer. It induces anti-cancer immune responses by converting immunologically "cold" tumors "hot" through the activation of innate and adaptive immune responses.
The Company is advancing pelareorep in combination with chemotherapy and checkpoint inhibitors in metastatic breast and pancreatic cancers, both of which have received Fast Track designation from the FDA. Oncolytics is actively pursuing strategic partnerships to accelerate development and maximize commercial impact. For more about Oncolytics, please visit: www.oncolyticsbiotech.com or follow the company on social media on LinkedIn and on X @oncolytics.
Logo: https://mma.prnewswire.com/media/2408622/Oncolytics_Biotech_Inc_Logo.jpg
Company Contact
Jon Patton
Director of IR & Communication
jpatton@oncolytics.ca
Investor Relations for Oncolytics
Mike Moyer
LifeSci Advisors
+1-617-308-4306
mmoyer@lifesciadvisors.com
Media Contact for Oncolytics
Owen Blaschak
LifeSci Communications
oblaschak@lifescicomms.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/oncolytics-biotech-announces-upcoming-annual-general-meeting-and-second-quarter-financial-results-302521769.html
SOURCE Oncolytics Biotech® Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.